DiaSorin slides on expectation of 'another year with no margin growth'

Shares in DiaSorin fall 17%, to a nine-year low, after the Italian medical diagnostics group issued 2026 guidance below expectations

DiaSorin eyes EBITDA margin guidance of 32%-33%, which is below Equita's estimate of 33.7%

The broker cuts its rating to "hold" from "buy" and its PT by 25% to 70 euros, citing weak start to the year and not seeing sufficient support for a significant top-line acceleration to meet guidance

It also flags growing reliance on new product launches and the 2026 respiratory season, as well as potential cost pressures and tariff impacts

"Another year of no margin growth," J.P. Morgan says, flagging further downside risk, expecting shares to possibly fall by a mid- to high-single-digit percentage

Banca Akros notes the diagnostics market is becoming increasingly challenging due to slowing volumes in Europe, China's VBP expansion and an uncertain regulatory and pricing environment